新型5-甲基-1,2,4-三唑-3-硫酮类化合物的合成及抗菌活性研究

利用生物活性叠加原理,以4-氨基-5-甲基-1,2,4-三唑-3-硫酮为原料,设计合成了15个未见报道的化合物2-N-2′,3′,4′,6′-四-O-乙酰基-β-D-吡喃葡萄糖基-4-N-取代苯基亚胺基-5-甲基-1,2,4-三唑(2a～2e),4-N-取代苄基氨基-5-甲基-1,2,4-三唑(3a～3e)和2-N-2′,3′,4′,6′-四-O-乙酰基-β-D-吡喃葡萄糖基-4-N-取代苄基氨基-5-甲基-1,2,4-三唑(4a～4e).其结构经IR,1H NMR,13C NMR和元素分析确认.生物活性测试表明,所有化合物均表现出一定的抑菌活性,尤其是化合物4b对大肠杆菌和金黄色葡萄球菌的最小抑菌浓度为8μg/mL,明显优于市售抗菌药物氟康唑,表现出较强的抗细菌活性;同时,与三氯生相比,所有化合物对白色念珠菌的最小抑菌浓度(MIC)均小于或等于32μg/mL,亦表现出较好的抗真菌活性.     

1-芳酰基-4-(1＇-N-β-D-吡喃型糖基)氨基硫脲类化合物的合成

通过2,3,4,6-四-O-乙酰基-β-D-吡喃型葡萄糖异硫氰酸酯和2,3,4-三-O-乙酰基-β-D-吡喃型木糖异硫氰酸酯与取代的芳基酰肼的亲核加成反应合成了10个1-芳酰基-4-(1＇-N-2＇,3＇,4＇,6＇-四-O-乙酰基-β-D-吡喃型葡萄糖基)氨基硫脲和7个1-芳酰基-4-(1＇-N-2＇,3＇,4＇-三-O-乙酰基-β-D-吡喃型木糖基)氨基硫脲,所得化合物的结构经元素分析,IR,1H NMR确证.     

3-(N-取代苯基-2-乙酰胺基)硫基-4-N-取代邻羟苯基亚胺基-5-甲基-1,2,4-三唑类化合物的合成及生物活性研究

以对称二氨基硫脲为原料,与冰醋酸反应生成5-甲基-4-氨基-1,2,4-三唑-3-硫酮(1);在弱酸性条件下,1与取代水杨醛反应生成席夫碱中间体5-甲基-4-(N-取代邻羟苯基)亚胺基-1,2,4-三唑-3-硫酮(2a～2c);最后在碱性条件下分别与N-取代苯基-2-氯乙酰胺发生烷基化反应生成15种未见报道的目标化合物3-(N-取代苯基-2-乙酰胺基)硫基-4-(N-取代邻羟苯基)亚胺基-5-甲基-1,2,4-三唑(3a～3o),其结构经IR,1H NMR,13C NMR确证.初步生物测试表明,质量分数为0.01%时,3a～3o对白色念珠菌的抑菌率均达90%以上,具有很强的抑菌活性;对金黄色葡萄球菌、大肠杆菌的抑菌率达80%以上,具有较强的抑菌活性.     

4-甲酰基苯基(2,3,4,6-O-四乙酰基)-β-D-葡萄糖苷衍生物的有效合成

为克服目前合成方法存在收率较低,反应时间长、产品分离困难等不足,本文以β-D-葡萄糖、乙酰溴为原料,经乙酰化、溴代反应合成了糖基体2,3,4,6-O-四乙酰基-α-D-溴代葡萄糖,再与4-羟基苯甲醛衍生物经糖苷化反应合成了5种4-甲酰基苯基(2,3,4,6-O-四乙酰基)-β-D-葡萄糖苷衍生物。在合成4-甲酰基苯基(2,3,4,6-O-四乙酰基)-β-D-葡萄糖苷衍生物的过程中,采用10%(质量分数) Na OH溶液为缚酸剂,三(3,6-二氧杂庚基)胺(TDA-1)为相转移催化剂,反应物的收率为61%～69%,并应用核磁共振技术确定了产品的结构。该方法具有产品收率较高,反应温和、操作简单等优点。     

3-烷基/芳基-6-(1'-N-β-D-或-α-L-吡喃型全乙酰化糖基)- 均三唑并[3,4-b]-1,3,4-噻二唑的合成

通过2,3,4,6-四-O-乙酰基-β-D-吡喃型葡萄糖异硫氰酸酯(3)和2,3,4-三-O-乙酰基-α-L-吡喃型鼠李糖异硫氰酸酯(4)与3-烷基/芳基-4-氨基-5-巯基-1,2,4-三唑(5)在乙醇中回流,缩合得到了14个新的3-烷基/芳基-6-(1'-N-2',3',4',6'-四-O-乙酰基-β-D-吡喃型葡萄糖基或2',3',4'-三-O-乙酰基-α-L-吡喃型鼠李糖基)-均三唑并[3,4-b]-1,3,4-噻二唑类化合物(6a-6i,7a-7e),化合物结构经元素分析、IR和1H NMR确证.     

1-(4-取代苯基)-4-苯基-5-(2-羟基苄基)氨基-1,2,3-三唑类衍生物的合成及抑菌活性

将邻羟苯基引入1,2,3-三唑结构中, 设计合成了10个1-(4-取代苯基)-4-苯基-5-取代-1,2,3-三唑类衍生物. 首先, 以对位取代的芳胺为原料, 经重氮化、叠氮化、闭环和缩合反应制得1-(4-取代苯基)-4-苯基-5-水杨醛亚胺-1,2,3-三唑类衍生物(3a~3e), 再用硼氢化钠还原制得1-(4-取代苯基)-4-苯基-5-(2-羟基苄基)氨基-1,2,3-三唑类衍生物(4a~4e). 目标化合物的结构经核磁、IR及元素分析确认. 抑菌活性测试表明, 当质量浓度为0.1 mg/L时, 除化合物3e和4e外, 所有化合物对白色念球菌的抑菌率均达95%以上, 对大肠杆菌的抑菌率达85%以上, 具有强抑菌活性, 表明该类化合物在抗菌药物开发方面有重要应用价值.     

3-O-(β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)哒嗪的合成与表征

利用6-(4-卤代苯基)-3(2H)-哒嗪酮的银盐(2)与2,3,4,6-四-O-乙酰基-1-溴-1-脱氧-α-D-吡喃葡萄糖(3)发生Koenigs-knorr反应, 合成了3-O-(2,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)哒嗪(4),4用干燥的氨气在0℃～-5℃下处理脱乙酰基保护基得相应的3-O-(β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)哒嗪(5).其结构经元素分析,IR及1H NMR证实.     

1-[3’-(4″-甲氧基苯基)-5’-甲基异噁唑-4’-甲酰基]-4-芳基氨基硫脲及其衍生物的合成

以3,5-二取代异噁唑-4-甲酰肼为基本原料制备关键中间体1-(3-对甲氧基苯基-5-甲基异噁唑-4-基)-4-芳基氨基硫脲(3a～3c);3在不同条件下经关环反应制得含有3,5-二取代异噁唑的2-芳氨基噻二唑(4a～4c),2-芳氨基噁二唑(5a～5c)和3-[3’-(4″-甲氧基苯基)-5’-甲基-异噁唑-4’-基)-4-芳基-1,2,4-三唑-5-硫酮(6a～6c);6与碘甲(乙)烷反应合成了4-芳基-5-[3’-(4″-甲氧基苯基)-5’-甲基异噁唑-4’-基]-3-甲(乙)硫基-1,2,4-三唑(7a～8c),其结构经1H NMR,IR,MS和元素分析表征,其中4,5,7和8未见文献报道。     

2,6-二甲基-3,5-二氯-4-吡啶酚糖苷的合成

在相转移催化条件下, 使 a-D-乙酰基化溴代的葡萄糖、半乳糖、葡萄糖醛酸甲酯1a, 1b, 1c分别与2,6-二甲基-3,5-二氯-4-吡啶酚(俗称氯吡醇, 氯羟吡啶)作用, 合成了氯吡醇的糖苷: 1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4,6-四-O-乙酰基-β-D-葡萄吡喃糖苷(2a), 1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4,6-四-O-乙酰基β-D-半乳吡喃糖苷(2b), 1-O-(2'6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4-三-O-乙酰基-β-D-葡萄吡喃糖醛酸甲酯(2c)。2a, 2b, 2c分别在甲醇中氨解, 相应得到: 1-O-(2', 6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-葡萄吡喃糖苷(3a), 1-O(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-半乳吡喃糖苷(3b),1-O-(2', 6'-二甲基-3',5'-二氯-(4'-吡啶基)-β-D-葡萄吡喃糖醛酸酰胺(3c)。2c用CH~3ONa/CH~3OH处理, 得到1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-葡萄吡喃糖醛酸甲酯(3d)。     

糖苷合成研究(ⅩⅩⅠ)2-N-(β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)-3-哒嗪酮的合成

在相转移催化条件下,2,3,4,6-四-O-乙酰基-1-溴-1-脱氧-α-D-吡喃葡萄糖1与6-(4-卤代苯基)-3(2H)-哒嗪酮2反应,合成了4种新的哒嗪酮葡萄糖苷3;然后用干燥的氨气在0～-5 ℃下处理,得相应的2-N-(β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)-3-哒嗪酮4. 这些化合物的结构经IR、1H NMR、13C NMR及元素分析所证实.     

Synthesis and Crystal Structure of 3,6-Bis（4-methyl-1,2,3-thiadiazol-5-yl）-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole

The compound 3,6-bis(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-triazolo[3,4-b][1,3,4] thiadiazole(C9H6N8S3,Mr = 322.40) has been synthesized by the reaction of 4-amino-3-(4-methyl-1,2,3-thiadiazolyl)-5-mercapto-1,2,4-triazole with 4-methyl-1,2,3-thiadiazol-5-carboxylic acid and phosphorus oxychloride,and its structure was characterized by IR,1H NMR,EI-MS,elemental analysis and single-crystal X-ray diffraction.The crystal of the title compound belongs to monoclinic,space group C2/c with a = 2.0053(4),b = 1.3081(3),c = 1.0556(2) nm,β = 112.69(3)°,Z = 4,V = 2.5548(9) nm3,Dc = 1.676 g/cm3,μ = 0.582 mm-1,F(000) = 1312,R = 0.0546 and wR = 0.1523.X-ray analysis indicates that all rings are essentially planar in this molecule,and an intermolecular hydrogen bond C(9)-H(9)…N(2) and weak intramolecular interactions between S(1)…N(7),S(3)…N(1) and S(2)…N(4) are observed.     

3-取代硫基-5-(1-羟基苯基)-4H-1,2,4-三唑类化合物的合成及抑菌活性

依据邻羟基二苯醚及三唑类化合物的抗菌特性及生物活性叠加原理, 将邻羟苯基和1,2,4-三唑分子片断有机结合, 设计合成了12个新型3-取代硫基-5-(1-羟基苯基)-4H-1,2,4-三唑类化合物. 首先, 水杨酸甲酯与水合肼反应生成水杨酰肼, 水杨酰肼再与硫氰酸铵和盐酸反应, 生成5-(1-羟基苯基)-4H-1,2,4-三唑-3-硫酮(3), 最后在碱性条件下化合物3与取代苯乙酮、氯苄和碘甲烷发生烷基化反应生成目标化合物, 化合物结构经 1H NMR及IR等表征确认. 抑菌测试结果表明, 当化合物质量分数为0.01%时, 目标化合物对白色念珠菌和大肠杆菌的抑菌率高达90%, 具有强抑菌活性; 对金黄色葡萄球菌的抑菌率高达80%, 具有一定的抑菌活性.     

Synthetic cephalosporins. VII. Synthesis and antibacterial activity of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-(3-(3-hydroxy-4-pyridon-1-yl)-3- carboxypropoxyimino)acetamido]-3-(1,2,3-thiadiazol-5-yl)-thiomethyl-3- cephem-4-carboxylic acid and its related compounds

Synthesis and antibacterial activity of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-(3-(3-hydroxy-4-pyridon-1-y l)-3- carboxypropoxyimino)acetamido]-3-(1,2,3-thiadiazol-5-yl)thio methyl-3-cephem-4-carboxylic acid (12a) and its related compounds are described. Compound 12a exhibited excellent antibacterial activity against gram-negative bacteria, including Pseudomonas aeruginosa.     

Bromo derivatives of 1-(4-hydroxyphenyl)dihydrouracil and 1-(4-hydroxyphenyl)-5- or -6-metehyldihydrouracils

Bromination of 1-(4-hydroxyphenyl)dihydrouracil and its 6-methyl derivative with bromine in refluxing acetic acid gave 1-(3,5-dibromo-4-hydroxyphenyl)-5-bromo-, 1-(3,5-dibromo-4-hydroxyphenyl)-5-bromo-, and 1-(3,5-dibromo-4-hydroxyphenyl)-5-bromo-6-methyldihydrouracils and 1-(3,5-dibromo-4-hydroxyphenyl)-5-methyluracil. 5-Bromo- and 5,5-dibromodihydrouracils were dehydrobrominated, and the same compounds undergo decomposition to 3,5-dibromo-4-hydroxyphenylurea upon alkaline hydrolysis.Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 9, pp. 1251–1254, September, 1982.     

Synthesis of 4-(pyrazol-5-yl)-1,2,4-triazole-3-thiones

Condensation of pyrazolyl isothiocyanates 2 with N-substituted hydrazines provided the 2-methyl/phenyl-4-(pyrazol-5-yl)thiosemicarbazides 3 . Cyclization of 3 with formic acid-acetic anhydride or with triethyl orthoacetate-acetic anhydride provided 4-(pyrazol-5-yl)-l,2,4-triazole-3-thiones 4a-f and 5-methyl-4-(pyrazol-5-yl)-1,2,4-triazole-3-thiones 4g-I respectively.     

Synthesis of 1,2,4- and 1,3,4-oxadiazoles from 1-aryl-5-methyl-1<Emphasis Type="Italic">H</Emphasis>-1,2,3-triazole-4-carbonyl chlorides

5-Substituted 2-(1-aryl-5-methyl-1H-1,2,3-triazol-4-yl)-1,3,4-oxadiazoles were synthesized by reaction of 1-aryl-5-methyl-1H-1,2,3-triazole-4-carbonyl chlorides with the corresponding 5-substituted 1H-tetrazoles. 5-Methyl-1-phenyl-1H-1,2,3-triazole-4-carbonyl chloride reacted with N′-hydroxybenzimidamides to give 3-aryl-5-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazoles. Reactions of 4-(5-methyl-1H-1,2,3-triazol-1-yl)benzoic acid with N′-hydroxybenzimidamides resulted in the formation of 3-aryl-5-[4-(5-methyl-1H-1,2,3-triazol-1-yl)phenyl]-1,2,4-oxadiazoles.     

Thiadiazole ring opening in the derivatives of 2-substituted 5-(1,2,3-thiadiazol-4-yl)-3-furoic acid under the action of bases

Transformations of the derivatives of 2-substituted 5-(1,2,3-thiadiazol-4-yl)-3-furoic acid under the action of bases has been studied. In the presence of potassium tert-butylate in THF, the studied compounds decompose with the cleavage of the thiadiazole ring, liberation of nitrogen, and formation of labile acetylene thiolates. In the presence of methyl iodide, these salts form stable 2-methylthioethynylfurans. Under the action of sodium ethylate in ethanol, thiadiazole ring of ethyl [2-methyl-5-(1,2,3-thiadiazol-4-yl)]-3-furoate is split to form the corresponding sodium acetylene thiolate. Under the action of ethanol, two molecules of this salt give bis(furyl)dithiafulvene. In the DMF–potassium carbonate system, acetylene thiolates react with primary and secondary amines giving thioamides of (4-ethoxycarbonyl-5-methylfur-2-yl)acetic acid. Treating of ethyl 2-methyland 2-N-morpholinomethyl-5-(1,2,3-thiadiazol-4-yl)-3-furoates with hydrazine hydrate leads to hydrazinolysis of the ester group and cleavage of thiadiazole ring resulting in the formation of hydrazides of 4-hydrazinocarbonylfur-2-ylacetic acid. In the case of ethyl 2-acetoxymethyl- and 2-(4-nitrophenoxy)methyl-5-(1,2,3-thiadiazol-4-yl)-3-furoates, thiadiazole ring is retained and exclusively hydrazinolysis of the ester groups is observed.     

Structural study and thermal behavior of novel interaction product of 4-amino-5-(furan-2-yl)-4H-1,2,4-triazole-3-thione with molecular iodine

Abstract

As a part of investigation of thyreostatic activity of mercapto-substituted triazoles, the structure, spectroscopic properties of 4-amino-5-(furan-2-yl)-4H-1,2,4-triazole-3-thione were obtained. 4-amino-5-(furan-2-yl)-4H-1,2,4-triazole-3-thione forms steady charge-transfer complex in dilute chloroform solution, coordinating one iodine molecule (lgβ?=?3.47). The reaction product of 4-amino-5-(furan-2-yl)-4H-1,2,4-triazole-3-thione is presented by uncharged adduct: C₆H₆N₄OS·I₂. The crystal structure of the adduct was studied in detail by single crystal X-ray diffraction. The results of thermogravimetric analysis revealed the stability of adduct in a solid state at the temperature range 50–500?°C.     

Reactions of 2-(5-methyl-2-phenyl-2H-1,2,3-diazaphosphol-4-yl)- 4H-1,3,2-benzodioxaphosphinin-4-one with chloral and hexafluoroacetone

Reaction of 2-(5-methyl-2-phenyl-2H-1,2,3-diazaphosphol-4-yl)-4H-1,3,2-benzodioxaphosphinin-4-one with chloral occurs at Piii atom of the 1,3,2-dioxaphosphinine cycle giving mostly 2-chlorocarbonylphenyl 2,2-dichlorovinyl (5-methyl-2-phenyl-2H-1,2,3-diazaphosphol-4-yl)phosphonate, whereas hexafluoroacetone incorporates into the 1,3,2-dioxaphosphorine cycle affording the corresponding 1,3,2-benzodioxaphosphepine.